Selecta Biosciences Receivables

Selecta Biosciences (SELB) currently reports a receivables of $260K as of March 2026. That compares with $1.8M in the prior-year period — down 85.2% year over year. Use the charts on this page to explore Selecta Biosciences's receivables history and peer comparisons.

Selecta Biosciences's receivables decreased from $1.8M to $260K — a 85.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Selecta Biosciences reported $260K in receivables as of March 2026. That compares with $1.8M in the prior-year period — down 85.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $260K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Selecta Biosciences, and consider following SELB for alerts when major investors trade the stock.

Selecta Biosciences is classified in the Healthcare sector. On receivables, it currently shows $260K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SELB with unrelated industries.